Trial Profile
Pilot Study of Safety and Efficacy of Lymphodepletion Followed by MG4101 Administered Intravenously to Patients With Refractory or Relapsed AML
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Apr 2023
Price :
$35
*
At a glance
- Drugs MG 4101 (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 16 Apr 2023 Status changed from recruiting to completed.
- 14 Dec 2021 Results(n=11) presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 23 Nov 2017 New trial record